NEU neuren pharmaceuticals limited

1.12%

$16.81

Preferisco l'italiano :)

First 9 Last

Share
Profile

Follow
w_i_z_z_a

309 Posts.

0

15/04/18

23:22

Post #: 32469046
Share

Originally posted by sillazze ↑

return to take stock of the situation by circumventing events that will inevitably mature from today to the end of May 2018. the reasoning is focused solely on details and certain events to be discounted in this time range, therefore without any personal assumptions and ergo :

It is certain that by the end of April the company will publish the annual report to shareholders revealing numbers, positions and related updates; after twenty working days from the publication of the annual report by rule there will necessarily be the AGM where the company will inevitably update the shareholders substantially on the progress made by the October FDA announcement to date.
the crucial particularity and on which the evolution of the market rests in complement to these events, are always the interests of the managers and their options to be discounted in ordinary shares. I briefly recall the constraints that allow maturation:

- employee or director of the company for at least 3 years from the issuance of the options.
-progress of at least one of the studies in phase 2b or 3 already authorized for a start by a national regulatory body (in our case we refer to the FDA ok already matured in last October).
-conclusion of a partnership transaction or material license.

two of these points are practically already realized; the third point to be defined is the green disk for assigning options. the options in question are 2.5 million of which 1 million await the constraint of 7 May 2018 as a mandatory deadline to be met, after which all 2.5 million have matured, but not in full since 50% of the same will also comply with a constraint that provides that the price on the market at that date (for a good portion is 7 May 2018) must be equal to or higher than $ 3.22 AU for at least 30 continuous trading days.

this explains the first attempts recently recorded to raise the price to a higher level given the approach day after day of the events mentioned.
it seems natural that it is obvious that by May and for at least a month to follow the Neuren title we should appreciate about 10% to satisfy the first interests in the field, that is those of the managers and managers of the company.

I hope I was clear

Hello

Expand

Preferisco l'italiano

NEU Price at posting: $3.00 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

AS2

Askari Metals outlines its African growth strategy and the pathway to drilling at Nejo

LISTEN: HotCopper Wire Podcast #052 – Finger lickin' not so good

ADVFN appoints Jason Paltrowitz as non-executive director

Expert Exchange: David Sokulsky on AI trade, chip stocks, and where to invest now

PSC

Prospect reshapes its Mumbezhi story with 'folded paper' and a 400m gamble

First 9 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last $16.81		Change -0.190(1.12%)		Mkt cap ! $2.147B

Open	High	Low	Volume
$16.99	$17.20	$16.67	81.30K

Buyers (Bids)

Vol.	Price($)
65	$16.81

Sellers (Offers)

Price($)	Vol.
$16.82	132

Last trade - 11.08am 03/07/2026 (20 minute delay)

NEU (ASX) Chart

Preferisco l'italiano :)

Askari Metals outlines its African growth strategy and the pathway to drilling at Nejo

LISTEN: HotCopper Wire Podcast #052 – Finger lickin' not so good

ADVFN appoints Jason Paltrowitz as non-executive director

Expert Exchange: David Sokulsky on AI trade, chip stocks, and where to invest now

Prospect reshapes its Mumbezhi story with 'folded paper' and a 400m gamble

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Preferisco l'italiano :)

Top Stories

Askari Metals outlines its African growth strategy and the pathway to drilling at Nejo

LISTEN: HotCopper Wire Podcast #052 – Finger lickin' not so good

ADVFN appoints Jason Paltrowitz as non-executive director

Expert Exchange: David Sokulsky on AI trade, chip stocks, and where to invest now

Prospect reshapes its Mumbezhi story with 'folded paper' and a 400m gamble

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News